Effective January 1, 2020, TRICARE revised its CGMS benefit to allow beneficiaries with uncontrolled diabetes the use of FDA-approved CGMS. This coverage includes both therapeutic and non-therapeutic devices. This change offers a potential cost savings to affected beneficiaries.
When beneficiaries submit a claim for a CGMS, the name of the device (ex. Freestyle Libre) should be visible on the receipt.
See Submit a claim for additional information.
